CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Joe Catanzaro - Piper Sandler Malcolm Kuno - JPMorgan Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen only-mode. ...

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced earnings of $0.04, delivering a surprise of 123.53%.Over the last four quarter ...

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 - - CX-801 (IFNα2b) Phase 1 clinical study initiation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma anticipated in 1st half of 2024 -   - Management to hold conference call today at 5 p.m. EDT / 2 p.m. ...

Exhibit 99.1 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., March 11, 2024 – CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update. "2023 was a year of sustained execution across our pipeline, highlighted by the continued progress of CX-904 in Phase 1 dose escalation and the parallel advancement of CX-2051 and ...

Pediatric Studies Biologic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive and record-keeping requi ...

CytomX Therapeutics (CTMX) is expected to report fourth-quarter and full-year 2023 results soon. In the last reported quarter, the company beat earnings expectations by 123.53%.Factors to NoteCytomX does not have any marketed product. Investor focus on the fourth-quarter 2023 earnings call will be on updates regarding key cancer immunotherapeutic candidates, CX-904 and BMS-986288.CX-904 is an EGFR-CD3 T-cell engager, developed in partnership with Amgen (AMGN) , while BMS-986288 is a non-fucosylated CTLA-4 t ...

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma also anticipated in 1H 2024 - SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it has received clearance from ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Roger Song - Jefferies. Jade Montgomery - H.C. Wainwright Etzer Darout - BMO Capital Markets Lukas Shumway - BMO Capital Markets Courtney Bahlman - Barclays Operator Good day and thank you for standing by. Welcome to the CytomX Therapeutics Third Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commis ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer Conference Call Participants Roger Song - Jefferies Priyanka Grover - JP Morgan Dipesh Patel - H.C. Wainwright Operator Good day, and welcome to the CytomX Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the sp ...